Recent studies showed that the different location of GPR30—cytoplasmic and nuclear locations—can reflect distinct tumor properties in breast cancer [44], and the lack of GPR30 expression in the plasma membrane can be associated with excellent long-term prognosis in ERα and PgR-positive tamoxifen-treated primary breast cancer [45]. The gene discussed is PGR; the disease is breast carcinoma.